C-erbB2-induced Epithelial-mesenchymal Transition in Mammary Epithelial Cells is Suppressed by Cell-cell Contact and Initiated Prior to E-cadherin Downregulation
Overview
Affiliations
Prolonged signalling from the growth factor receptor subunit and proto-oncogene c-erbB2 has been shown to cause epithelial-mesenchymal transition (EMT) in mammary epithelial cells. Using a system where c-erbB2 homodimer signalling can be induced in human mammary epithelial cells, we characterised the properties of c-erbB2-induced EMT. The cells resulting from this transdifferentiation showed a pronounced and stable fibroblastic phenotype with spindle-like morphology, homogeneous high expression of vimentin, N-cadherin, and integrin alpha5 as well as loss of E-cadherin and desmoplakin. However, the rate at which EMT occurred was very slow compared to other reported systems, as complete conversion was not seen until after 12-15 weeks of c-erbB2 signalling. This time delay was however not due to the presence of long-lived intermediate cell types as measured by expression of combinations of markers. By studying morphological time-courses of individual colonies of epithelial cells subjected to c-erbB2 signalling, we could conclude that apart from EMT, c-erbB2 could also cause transition to very large cells retaining cell-cell contact but with little or no proliferative capacity. EMT preferentially occurred in small colonies, suggesting that extensive cell-cell contact inhibits EMT. When testing this conclusion by exposing cells to c-erbB2 signalling at different cell densities, we concluded that only cells kept at low density would undergo EMT. High cell density also prevented the proliferative decrease associated with prolonged c-erbB2 signalling. Immunofluorescence microscopy revealed that disruption of cell-cell contact was preceded by partial relocalisation of beta-catenin to the cytoplasm whereas downregulation of E-cadherin appeared to occur after initiation of cell scattering.
Goncharov A, Vashakidze N, Kharaishvili G Biomedicines. 2024; 12(2).
PMID: 38398019 PMC: 10886988. DOI: 10.3390/biomedicines12020418.
Chang C, Liang T, Lam H Biomolecules. 2024; 14(1).
PMID: 38254674 PMC: 10813220. DOI: 10.3390/biom14010074.
Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang J, Khoury J Cancers (Basel). 2022; 14(21).
PMID: 36358657 PMC: 9656921. DOI: 10.3390/cancers14215238.
Giusti V, Ruzzi F, Landuzzi L, Ianzano M, Laranga R, Nironi E Oncogenesis. 2021; 10(11):77.
PMID: 34775465 PMC: 8590694. DOI: 10.1038/s41389-021-00360-9.
Nami B, Ghanaeian A, Black C, Wang Z Life (Basel). 2021; 11(9).
PMID: 34575017 PMC: 8472246. DOI: 10.3390/life11090868.